Result of AGM

RNS Number : 2251A

IXICO plc

17 January 2020

 

17 January 2020

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, can announce that resolutions one to five were put forward to its Annual General Meeting held earlier today and were duly passed whilst resolution six was not duly passed. The votes cast at the meeting were as follows:

Resolution	Description	Total Votes For	% Votes	Total Votes Against	% Votes	Withheld	Votes cast as a % of ISC
1	Reports and Accounts	21,954,961	100.00%	200	0.00%	800	46.62
2	Re-election of Directors
2a	Re-election of Giulio Cerroni	21,955,461	100.00%	500	0.00%	0	46.62
2b	Re-election of Grant Nash	21,955,461	100.00%	500	0.00%	0	46.62
3	Re-appointment of Auditors	21,949,261	99.99%	1,700	0.01%	5,000	46.61
4	Allotment of Securities	21,953,961	99.99%	1,700	0.01%	300	46.62
5	Disapply Pre-Emption Provisions	21,953,761	99.99%	1,900	0.01%	300	46.62
6	Amendment of Rule 3 of the Long-Term Incentive Plan	10,641,004	48.48%	11,309,157	51.52%	5,800	46.61

Charles Spicer, Chairman of the Board of IXICO, commented:

"The board notes the results of the resolution to approve the amendment to the IXICO LTIP and, over the coming months, will engage with those major shareholders who did not support this resolution to understand their concerns."

For further information please contact: IXICO plc Giulio Cerroni, Chief Executive Officer [phone] Grant Nash, Chief Financial Officer Cenkos Securities PLC (Nominated adviser and sole broker) Giles Balleny / Max Gould (Corporate Finance) Michael F Johnson / Russell Kerr (Sales) [phone] Optimum Strategic Communications Mary Clark, Supriya Mathur, Manel Mateus [e-mail] [phone]

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

 

END

 

 

RAGKKOBNABKDBDD